Centogene

Schillingallee 68
Rostock
18057
Germany

Tel: 49-381-203652-0

Show jobs for this employer

189 articles about Centogene

  • Centogene N.V. announced that it has extended its partnership with Takeda Pharmaceutical Company Limited to diagnose patients with certain genetic disorders.

  • Centogene N.V., a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced that it will issue a press release reporting its financial results for the full year ended December 31, 2020, on Thursday, April 15, 2021, and will host a conference call to discuss these results at 8 a.m. EDT that day.

  • Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of the disease progression, diagnosis, and treatment Significant milestone of 10,000 participants reached With over 120 study sites around the world, CENTOGENE is leading the largest corresponding study for genetics in Parkinson’s disease ever performed

  • Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, today announced the voting results of the Company’s Extraordinary General Meeting. The shareholders of the Company voted in favor of all proposals, which included t

  • Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today provided an update on its corporate progress and reported its financial results for the three and nine months ended September 30, 2020. Revenues increased

  • Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, and Alnylam Pharmaceuticals, Inc. (“ Alnylam ”), the leading RNAi therapeutics company, announced today the launch of a new joint clinical screening program: the genetic scre

  • CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced the nomination of Dr. Jonathan G. Sheldon as a member of the Supervisory Board, which will be proposed to the shareholders at an upcoming Extraordinary General Meeting (EGM). Dr. Shel

  • Centogene N.V. and Fujirebio Europe announced to have entered a partnership to leverage LUMIPULSE® G technology for large-scale COVID-19 antigen testing with further deployment in German airports.

  • CENTOGENE expands its SARS-CoV-2 testing solution to Berlin Brandenburg Airport (BER) after successfully launching COVID-19 test centers at three major German airports in cooperation with Lufthansa

  • Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
  • Centogene N.V., a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced it is increasing full-year 2020 guidance and now anticipates revenues greater than €80 million.

  • Centogene N.V., a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced that Prof. Arndt Rolfs, the Company’s Chief Executive Officer and founder, has decided to step down as CEO of CENTOGENE as of October 20, 2020, and that Andrin Oswald, M.D., will join the Company as CEO on December 1, 2020.

  • Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
  • Centogene N.V., a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced that the U.S. Food and Drug Administration has issued Emergency Use Authorization for ‘CentoSure’, the company's latest SARS-CoV-2 RT-PCR test.

  • Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, and U-Diagnostics B.V., a Dutch medical laboratory, specialized in analysis in the field of clinical chemistry and hematology, medical microbiology, medical immunology

  • Centogene N.V. announced that that the Company has been awarded ISO/IEC 27001:2017 certification following an extensive audit of its Information Security Management System.

  • Centogene N.V., a commercial-stage company focused on rare diseases that transforms real- world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, provided an update on its corporate progress and reported its financial results for the three and six months ended June 30, 2020.

  • Centogene N.V., a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced the opening of its new COVID-19 testing facility at Düsseldorf Airport.

  • Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that it will issue a press release reporting its financial results for the six months ended June 30, 2020 on Wednesday, September 23, 2020, and will host a conference call to

  • Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 11, 2020.